Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy

Nobuhiro Hara; Takamichi Miyamoto; Takamasa Iwai; Junji Yamaguchi; Sadahiro Hijikata; Keita Watanabe; Yuichiro Sagawa; Ryo Masuda; Ryoichi Miyazaki; Naoyuki Miwa; Masahiro Sekigawa; Tetsuo Yamaguchi; Yasutoshi Nagata; Toshihiro Nozato; Toru Obayashi

doi:10.3400/avd.oa.17-00054

ORIGINAL ARTICLES

Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy

Nobuhiro Hara , Takamichi Miyamoto, Takamasa Iwai, Junji Yamaguchi, Sadahiro Hijikata, Keita Watanabe, Yuichiro Sagawa, Ryo Masuda, Ryoichi Miyazaki, Naoyuki Miwa, Masahiro Sekigawa, Tetsuo Yamaguchi, Yasutoshi Nagata, Toshihiro Nozato, Toru Obayashi

Author information

Nobuhiro Hara Corresponding author
Department of Cardiology, Japanese Red Cross Musashino Hospital
Takamichi Miyamoto
Department of Cardiology, Japanese Red Cross Musashino Hospital
Takamasa Iwai
Department of Cardiology, Japanese Red Cross Musashino Hospital
Junji Yamaguchi
Department of Cardiology, Japanese Red Cross Musashino Hospital
Sadahiro Hijikata
Department of Cardiology, Japanese Red Cross Musashino Hospital
Keita Watanabe
Department of Cardiology, Japanese Red Cross Musashino Hospital
Yuichiro Sagawa
Department of Cardiology, Japanese Red Cross Musashino Hospital
Ryo Masuda
Department of Cardiology, Japanese Red Cross Musashino Hospital
Ryoichi Miyazaki
Department of Cardiology, Japanese Red Cross Musashino Hospital
Naoyuki Miwa
Department of Cardiology, Japanese Red Cross Musashino Hospital
Masahiro Sekigawa
Department of Cardiology, Japanese Red Cross Musashino Hospital
Tetsuo Yamaguchi
Department of Cardiology, Japanese Red Cross Musashino Hospital
Yasutoshi Nagata
Department of Cardiology, Japanese Red Cross Musashino Hospital
Toshihiro Nozato
Department of Cardiology, Japanese Red Cross Musashino Hospital
Toru Obayashi
Department of Cardiology, Japanese Red Cross Musashino Hospital
Department of Health Science, Gunma Paz College

Keywords: edoxaban, DOAC, venous thromboembolism, malignancy

JOURNAL OPEN ACCESS

2017 Volume 10 Issue 4 Pages 407-410

DOI https://doi.org/10.3400/avd.oa.17-00054

Browse “Advance online publication” version

Details

Abstract

Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy.

Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between September 2014 and August 2015. We retrospectively examined the presence or absence of recurrent symptomatic VTE, VTE-related mortality, and bleeding events.

Results: No recurrent symptomatic VTE or VTE-related deaths were recorded, enabling efficient assessment. Treatment safety was determined based on the reports of bleeding. Bleeding was reported in two patients, with serious bleeding in one of them.

Conclusion: Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy.

Corresponding author

Correction information

Register with J-STAGE for free!